Search

everythinglearnresearchcommunity

for

Search:↓

PrEP for HIV is less effective in transgender women mainly due to low adherence to the treatment.

Transgender women can develop feminine traits and improve their quality of life through hormone therapy and surgery, but results vary and access to surgery can be limited.

Transgender women can still get testicular cancer, so proper screening is important.

Doctors are preparing to potentially perform uterus transplants in transgender women, considering technical, hormonal, and ethical factors.

Transgender women on estrogen therapy can develop melasma and need proper skin care.

Spironolactone and finasteride are equally effective for hirsutism in transgender women.

Oral estradiol works for many transgender women but needs personalized dosing and monitoring.

Hormone therapy with estradiol and spironolactone can regrow scalp hair in transgender women by lowering testosterone to female levels.

Uterine transplants for transgender women are feasible but need more research.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

Ciclosporin can cause excessive hair growth even with testosterone blockers.

The treatment helped a transgender woman stop drinking, improved her mental health, and reduced her gender dysphoria.

Hair transplants are effective for some women and many male-to-female transgender patients if done carefully by an experienced team.

Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.

The best treatment varies per individual, but options include minoxidil, finasteride, PRP, and LLLT.

The best treatment varies based on individual needs and available research.

The patient was satisfied with hormone therapy, and her epilepsy remained stable.

GnRH-a or orchiectomy is more effective than anti-androgens for managing hormone levels in transgender women.

Transgender women have similar fitness to cisgender women, while transgender men have higher fat and lower strength than cisgender men; hormone therapy affects body composition and strength.

The document concludes that more inclusive research involving the transgender community is needed, especially on the neovaginal microbiome of trans women.

Inclusive and culturally competent healthcare is crucial for transgender and non-binary individuals.

Testosterone increases hair growth and acne in transgender men.

High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.

Facial feminization surgery is safe and patients are satisfied, but more detailed research is needed.

The guideline emphasizes a multidisciplinary approach and informed consent for gender-affirming hormone treatment, with regular follow-ups and individualized care.

Gender-affirming hormone therapy improves physical performance in trans men to the level of cisgender men, while in trans women, it increases fat mass and decreases muscle mass, with no advantage in physical performance after 2 years.

Younger transgender women have surgery earlier, are mostly attracted to men, and show more preoperative depression that improves after surgery compared to older transgender women.

Hormone therapy may increase migraines in transgender women and decrease them in transgender men; more research is needed on migraine management in transgender individuals.

Transgender patients on masculinizing hormones have higher hair loss rates than cisgender women.

Hormone therapy increases the risk of heart-related issues in transgender women and may affect heart health in transgender men.